secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001193125-25-228293
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics cuts workforce 50% and delays BDC-4182 data to Q3 2026
---------------------------------------------------------------------------

- Workforce reduced by ~50% (approx. 20 employees); pre-tax charges $1.5-2.0M in Q4 2025.
- Phase 1 study of BDC-4182 (claudin 18.2 ISAC) showing strong immune response; protocol modified for step-up dosing.
- Initial clinical data for BDC-4182 now expected in Q3 2026, later than previously anticipated.
- Cash runway extended into 2027 via restructuring and workforce reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000119312525228293/0001193125-25-228293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000119312525228293/bolt-20251001.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-228293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer